Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Reasons for AVNR@$56.00
Milestones for Development of Novel Therapeutics for Inflammation
w/Novartis ..................................................................... April 2005
http://www.b2i.us/profiles/investor/ResLibraryView.asp?ResLibraryID=9311&GoTopage=6&BzID=958....
Over 200 million in milestone payments.
Progress ..................................................... Milestones Payments
Any day now phase I ............................................. $
?????????????? phase II ............................................ $$
????????????? phase III .............................................. $$$
FDA approval ......................................................... $$$$
Milestones for Novel Reverse Cholesterol Transport Enhancing Compounds
w/AstraZeneca PLC ......................................................... July 2005
http://www.b2i.us/profiles/investor/ResLibraryView.asp?ResLibraryID=10424&GoTopage=4&BzID=95....
Upfront 10 million w/milestones up to 330 million
Progress ................................................... Milestones Payments
Jan 2006 phase 1 ................................................ rec'd 5 million milestone
?????????????? phase II ............................................ $$
?????????????? phase III ............................................ $$$
FDA approval......................................................... $$$$
One Self funded phase III trial
Diabetic Neuropathic Pain.................................. began June 2005
http://www.b2i.us/profiles/investor/ResLibraryView.asp?ResLibraryID=10106&GoTopage=5&BzID=95....
Completed NDA for involuntary emotional expression disorder, also known as pseudobulbar affect or emotional lability..... Jan 2006
(a) Avanir's Neurodex NDA accepted with priority review for Involuntary Emotional Expression Disorder..... April 2006
(b) Avanir completed the submission of its NDA to the FDA on January 27, 2006 and expects the FDA will take action on the NDA by July 30, 2006 (the "PDUFA date").
http://biz.yahoo.com/ap/060404/avanir_neurodex.html?.v=1
The Company's first commercialized product, abreva®, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores.
http://www.b2i.us/profiles/investor/ResLibraryView.asp?ResLibraryID=13674&GoTopage=2&BzID=95....
Further information about Avanir can be found at http://www.avanir.com/
Stock ready to move:
MSN Money Opinion:
http://moneycentral.msn.com/investor/invsub/analyst/recomnd.asp?Symbol=AVNR
http://moneycentral.msn.com/investor/srs/srsmain.asp?Symbol=AVNR
Five Analyst opinions for the next 52 wks.
High Target: $56.00
Low Target: $23.00
Median Target: $30.00
http://finance.yahoo.com/q/ao?s=AVNR
Cramer's take on AVNR:
http://www.thestreet.com/_yahoo/funds/madmoneywrap/10278701_2.html
Avanir's Promising Prospect
Avanir Pharmaceuticals (AVNR:Nasdaq - commentary - research - Cramer's Take) just listed on the Nasdaq (it used to trade on the Amex), and, Cramer said, it's time to buy the stock because the Food and Drug Administration has given some of its formulations priority status.
The only thing better than a company having pull with the government is a company that has products so good that it doesn't need pull with the government, he said.
One of these treatments is Neurodex, which treats pseudobulbar affect (PBA). This condition, which often afflicts people with Lou Gehrig's disease and multiple sclerosis, causes uncontrollable bouts of laughter or tears. The FDA has given Neurodex fast track status, and Cramer said that it should be able to do $150 million in sales if it is approved.
http://biz.yahoo.com/ap/060404/avanir_neurodex.html?.v=1
Better still, he said that the treatment could also get "orphan drug status," giving it a seven-year monopoly in addition to patent protection.
The company is working with Novartis (NVS:NYSE ADR - commentary - research - Cramer's Take) on deals that could earn Avanir $200 million in milestone payments, and is also involved in deals with AstraZeneca (AZN:NYSE ADR - commentary - research - Cramer's Take).
http://www.b2i.us/profiles/investor/ResLibraryView.asp?ResLibraryID=13674&GoTopage=2&BzID=95...
DAY PLAYS/IN PLAY: CHARTS THURSDAY MAY 18TH
IPRE MRKL CBAY ASHD AVLN AVNT CGHI CLXN DNAG FASC FLCRE HIET
HRSH IBTGF JLHY NNSR PRNW SNIO SPAB UTSYF VLTA TNSX AAGM ACUR FLIP ARFRE ADVC PGPM CHDT ARGY IPMG CVAS DDSI EGSR ADZR AOGS ATVE GCOG HOGC IACH IGAI NMXC NNSR QMMG SDRT SKFTE VACM VYST XDSL YTLIE DGKO EMXC GEMM HISC LBTN TGTL ESGR CITC IPMG IDCN SSSU TNOG XKEM VRDM TCLL SVMI SEVI IPMG BAWC LBWR HKBV LTXX
CKEI SQUM KLGE
Observations on the QQQQ from today and for tomorrow:
Please remember to extend the courtesy of clicking on the "VOTE FOR IT" link at the bottom of the web site:
http://stockcharts.com/def/servlet/Favorites.CServlet?obj=ID735617
XMSR is a member of the NASDAQ 100 as of Monday morning. It is therefore added to my real-time charts:
http://stockcharts.com/def/servlet/Favorites.CServlet?obj=ID735617&cmd=show[s41192886]&disp=....
Speaking of the QQQQ, $40 is the "Line In The Sand":
http://stockcharts.com/def/servlet/Favorites.CServlet?obj=ID735617
Check out DNDN. It issued good news on Saturday about its treatment for breast cancer that will affect the price tomorrow:
http://biz.yahoo.com/prnews/041211/sfsa001_1.html
DNDNs Chart:
http://stockcharts.com/def/servlet/Favorites.CServlet?obj=ID735617&cmd=show[s41192864]&disp=....
NXTL - $30 is huge breakout to all-time-high. There is no resistance for a stock that is prining new all-time-highs.
Check out the Real-Time Chart:
http://stockcharts.com/def/servlet/Favorites.CServlet?obj=ID735617&cmd=show[s36984915]&disp=...
'Support & Resistance Report' Subscribers...
You observed how well today's area of 'Gathering Support' for the QQQQ worked this morning.
Now, take note of where today's area of 'Gathering Resistance' for the QQQQ is located and feel free to act on it.
Areas of 'Gathering Support' (Buy Triggers) and areas of 'Gathering Resistance' (Sell Triggers) for this Index and the 21 stocks and indexes that follow are published in the 'Support & Resistance Report' that is emailed nightly.
http://stockcharts.com/def/servlet/Favorites.CServlet?obj=ID735617
Charts & Comments...
Please remember to extend the courtesy of clicking on the "VOTE FOR IT" link at the bottom of the web site:
http://stockcharts.com/def/servlet/Favorites.CServlet?obj=ID735617
Thanks,
opticalnet
Charts and Comments:
Each Chart highlights Double and Triple-Top Breakouts and Double and Triple-Bottom Breakdowns.
Please remember to extend the courtesy of clicking on the "VOTE FOR IT" link at the bottom of the web site:
QQQ, NASDAQ, S&P 500, DOW, SOX, SMH, AMLN, AMZN
http://stockcharts.com/def/servlet/Favorites.CServlet?obj=ID735617
CREE, DNDN, EBAY, IMCL, KLAC and MAGS
http://stockcharts.com/def/servlet/Favorites.CServlet?obj=ID735617&cmd=show[s36984906]&disp=...
MLNM, NVDA, NXTL, OSIP, QCOM, RIMM, SNDK
http://stockcharts.com/def/servlet/Favorites.CServlet?obj=ID735617&cmd=show[s36984915]&disp=...
TASR
http://stockcharts.com/def/servlet/Favorites.CServlet?obj=ID735617&cmd=show[s36984924]&disp=...
Trade Well !
mr_nasdaq
The QQQ could rise as high as $39.35 today without distroying the formation of the bearish 'Rishing Wedge' that has taken shape on the daily chart.
It must be noted, however, that sellers are needed in order for a 'Rising Wedge' to work it's magic, and there are none in sight.
The $SOX printed a "Double-Top Breakout" yesterday when it printed 428.
If it can now hold in the vicinity of 428, higher prices are sure to come.
Followers
|
0
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
35
|
Created
|
11/14/04
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |